
Opinion|Videos|January 29, 2025
Strategies to Managing Cardiotoxic AEs with Osimertinib
Strategies for managing cardiotoxicity in patients on osimertinib are discussed, focusing on monitoring adverse events and balancing symptom management with maintaining treatment efficacy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What strategies do you use for managing cardiotoxicity in patients on osimertinib?
- How do you monitor these adverse events and balance symptom management with maintaining treatment efficacy?
Advertisement
Related to this article

Lisa Carter-Bawa, PhD, MPH, APRN, explains how blame keeps patients from lung cancer care and how nurses can counter that stigma in the community.

At the 10th Annual School of Nursing Oncology, faculty said nurses need fast, disease-specific updates to educate patients and manage novel therapies.

Experts detail evidence for exercise, acupuncture, and mind-body care during radiation, and the knowledge and referral gaps that limit uptake.

Coral Omene, MD, PhD, discusses the clinical impact of breast cancer disparities and how oncology nurses can support diverse trial recruitment.

An ONS review presented at EONS19 outlines 7 system-level employer strategies to curb oncology nurse burnout and improve retention.

A Columbia nurse scientist shares her takeaways from the 2026 ASCO Quality Care Symposium, from geriatric assessment to care across the age span.

A patient, a caregiver, nurses, an NP, and an oncologist discuss rash prevention, dose holds, cost, and trial eligibility with oral daraxonrasib.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Declines Ivonescimab Approval in EGFR+ NSCLC Over Survival Data
2
Childhood Cancer Survival Climbs to 90%, but Racial Gaps Persist
3
FDA Approves Pertuzumab Biosimilar Pebrilzo for HER2+ Breast Cancer
4
Chemotherapy May Speed Biological Aging in Breast Cancer Survivors
5

